WORLD-RENOWNED STEM CELL RESEARCHER AND BOARD-CERTIFIED SURGEON, DR. BRIAN MEHLING, SET TO ATTEND THE 50TH ANNUAL WORLD ECONOMIC FORUM IN DAVOS

The 2020 World Economic Forum (WEF) in Davos will explore the ideas, innovations and discoveries that are reshaping our world by working closely with those in the vanguard of change from such fields as the arts, culture, engineering, media, medicine, science, and technology.
The US-based company BHI Therapeutic Sciences (BHITS) represented by Brian Mehling, MD, Founder and Chief Medical Officer; Klara Doert, President of International Business Development; Katarina Novakova, MSc, President of BHI Slovakia ; Alan Pereira, President of BHI Brazil ; Marko Cuka, CTO; and Melieck Robinson, International Consultant; is set to attend the annual meeting and participate in conversations, networking events, and attend sessions and panel discussions. This is the eight year, the organization will send representatives to the meeting.
Dr. Mehling explained what stem cells could mean to global health, and how it is creating a future in which many chronic conditions and diseases will be managed with stem cells rather than allopathic medicine or traditional medicine.
“Stem cell treatments are, without a doubt, the future of medicine.” Dr. Mehling states. “It is very important that people making decision on what direction the world will take in regards to research and medical treatments, are educated about not only the possibilities in stem cell research but also about all the treatments that are already available for many patients with different chronic conditions, ” he added.
“By strategically placing our clinic in Slovakia, the heart of Europe, the most innovative research and treatments within the stem cell field is available for the global markets, just 45 minutes away from Vienna International airport, “ said Ms. Novakova.
For more information please visit www.bhisciences.com

BRIAN MEHLING, MD AND BHI THERAPEUTIC SCIENCES TO PRESENT RESEARCH AT AAOS ANNUAL MEETING

Orthopedic surgeon Brian Mehling, MD and his research team at BHI Therapeutic Sciences will exhibit at the American Academy of Orthopedic Surgeons 2020 Annual Meeting, March 24 – 28, at the Orange County Convention Center in Orlando, Florida.

The team will present the results of their study entitled “Adipose Tissue-Derived Stromal Vascular Fraction Cells Application in Subjects with Osteoarthritis and Rheumatoid Arthritis: Retrospective Chart Review Study.” Their results will be presented at booth #1004 located in the West Concourse of the convention center.

“Musculoskeletal disorders are one of the most common reasons that patients seek medical care. The most common musculoskeletal problems are osteoarthritis and rheumatoid arthritis, said Dr. Mehling. “Adipose tissue-derived Stromal Vascular Fraction (SVF) cell therapy is a promising therapeutic option for rheumatoid arthritis and osteoarthritis,” he added.

 Dr. Mehling and his team conducted the current retrospective chart review study to analyze the therapeutic efficacy of SVF cells administration in 350 subjects with rheumatoid arthritis and osteoarthritis. In the period from 2015 to 2018, 350 subjects received an intra- articular injection of autologous SVF cells at the Malacky Hospital (Bratislava, Slovakia). The hospital is fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Bratislava, Slovakia. The study was approved by the Ministry of Health of the Slovak Republic and by the Institutional Review Board of the Institute of Regenerative and Cellular Medicine (IRCM-2017- 137). 

“Charts were reviewed, and information from subjects’ pain and mobility assessment scales, conducted seven days, three, six and 12 months after therapy, was collected in the data collection forms,” said Marina Manvelyan, Ph.D., clinical research scientist, BHI Therapeutic Sciences.   

Assessment of pain and mobility was conducted seven days, three, six and 12 months after SVF cell therapy. Significant decrease in subjects’ pain levels and improvement in mobility were observed three, six and 12 months compared to seven days after therapy. The therapy demonstrated a strong safety profile with no severe adverse events or complications reported.

Dr. Mehling is a practicing American orthopedic trauma surgeon and researcher. He is spearheading groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells. 


Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University.


Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University).


Dr. Mehling operates practices in northern New Jersey and Long Island, New York where he is on staff at Good Samaritan Hospital, Hackensack University Medical Center, Hackensack University Medical Center at Pascack Valley, Hackensack Meridian Palisades Medical Center, Hudson Regional Hospital, St. Joseph’s Medical Center, and St. Joseph’s Wayne Medical Center.

Founded in 1933, the Academy is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world. Its continuing medical education activities include a world-renowned Annual Meeting, multiple CME courses held around the country and at the Orthopaedic Learning Center, and various medical and scientific publications and electronic media materials.

Blue Horizon International Ambassador Lance Palmer becomes PFL’s first multi-millionaire

On December 31, 2019, Lance Palmer celebrated the new year by defeating Alex Gilpin in a unanimous decision win at Madison Square Garden. The victory gave Palmer the featherweight title for the second year in a row, and another million dollars.
Palmer—a former All-American wrestler and current MMA champion in the Featherweight Division—credits stem cell treatments from Blue Horizon International (BHI) with a greater feeling of overall health and energy, and more rapid recovery from training. Palmer received his treatments at the BHI Jamaica, Montego Bay Clinic. “My first stem cell treatment was in 2016,” says Palmer. “I would definitely recommend stem cells to athletes: it helps with the recovery process, preventing injury, and increase in overall energy. I’ve gotten better in the last two years than I have the previous six. I highly recommend Dr. Brian Mehling. He has been most helpful and explained the process step by step. I’ve had a great experience in BHI Jamaica.” BHI Therapeutics Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading scientists and physicians across the globe, utilizing stem cells from either your own body (autologous) or from umbilical cord donors. These donors go through a rigorous testing process to ensure their safety.We do not use embryonic stem cells, nor will we ever—health and safety are our number one priority. We ensure the highest standards of patient safety at our Jamaica Clinic through the collaborative efforts of a Scientific Advisory Board, Ethics Committee, and a staff of US board-certified Physicians. BHI Therapeutics Jamaica provides therapies for neurologic disorders,autoimmune diseases, and orthopedics conditions. For more information please visit www.bhisciences.com

Blue Horizon International exhibits at World Congress on Anti-Aging Medicine in Las Vegas

Blue Horizon International (BHI), Alpha Blu Skin Care, BHI Therapeutic Sciences, and BHI Rejuve participated in the 27th World Congress on Anti-Aging Medicine & Exhibition in Las Vegas, December 13-15, 2019.
Brian Mehling, M.D. , Founder and Chief Medical Officer of BHI was joined by Klara Doert, President of International Business Development; Katarina Novakova, Director of Relations; Alan DaSilvaPereira, President of BHI Brazil; Fidel Desmar, Clinical Research Coordinator; Ralph Moffetone and John-David Grayson from Industrial Motion Pictures.
BHI Therapeutic Sciences (BHITS) is led by an accomplished scientific and medical team and draws on its relationship with international partners who have successfully treated thousands of patients with stem cell therapy. BHITS was formed to perform research regarding, and to monetize, stem cell technology and associated regenerative medicine. Stem cells are a special type of human cell that can be used to regenerate the human body, in some cases, without drugs or surgery. Regenerative medicine professionals will soon seek to use stem cells to treat various diseases, to extend lifespans and improve the quality of life for certain patients
BHI Rejuve program focuses on anti-aging of the human body, with the help of a complex of vitamins, hormones and stem cell therapy. But the anti-aging part of BHI activities is only one component. Its program is more complex and offers advanced stem cell therapy to patients worldwide.

Blue Horizon International Ambassador Lance “the Party” Palmer is ready to party on New Years Eve in Madison Square Garden in NYC

Lance Palmer will be facing Alex Gilpin on December 31, 2019 at the Madison Square Garden in New York City. The fight will air at 7 p.m. EST on ESPN 2.

Palmer—a former All-American wrestler and current MMA champion in the Featherweight Division—credits stem cell treatments from Blue Horizon International (BHI) with a greater feeling of overall health and energy, and more rapid recovery from training.

Palmer received his treatments at the BHI Jamaica, Montego Bay Clinic. “My first stem cell treatment was in 2016,” says Palmer. “I would definitely recommend stem cells to athletes: it helps with the recovery process, preventing injury, and increase in overall energy. I’ve gotten better in the last two years than I have the previous six. I highly recommend Dr. Brian Mehling. He has been most helpful and explained the process step by step. I’ve had a great experience in BHI Jamaica.”

Dr. Brian Mehling with PFL Featherweight Champion Lance Palmer

BHI Therapeutics Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading scientists and physicians across the globe, utilizing stem cells from either your own body (autologous) or from umbilical cord donors. These donors go through a rigorous testing process to ensure their safety. We do not use embryonic stem cells, nor will we ever—health and safety are our number one priority. We ensure the highest standards of patient safety at our Jamaica Clinic through the collaborative efforts of a Scientific Advisory Board, Ethics Committee, and a staff of US board-certified Physicians. BHI Therapeutics Jamaica provides therapies for neurologic disorders, autoimmune diseases, and orthopedic conditions.

Check us out before the next decade! Check us out today! 

www.bluehorizoninternational.com

Come party with The Party as he squares off against  Alex Giplin at the Garden tonight! Airs at 7 pm at ESPN 2.

BRIAN MEHLING, MD AND MARINA MANVELYAN, PH.D RECEIVE MEMBERSHIP TO THE PRESTIGIOUS INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH

Hackensack, NJ – BHI Therapeutic Sciences is pleased to announce that Brian Mehling, MD, Chief Medical Officer and Marina Manvelyan, Ph.D., Clinical Research Scientist have been accepted as members of the prestigious International Society for Stem Cell Research (ISSCR).

Members of the ISSCR have been sharing global stem cell science for more than 15 years. With roughly 4,000 members from more than 60 countries, the ISSCR is the pre-eminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The organization promotes global collaboration among the world’s most talented and committed stem cell scientists and physicians, and plays a catalyzing role in the development of effective new treatments. 

According to George Q. Daley, MD, Ph.D., dean, Harvard Medical School and professor, Boston Children’s Hospital & Dana Farber Cancer Institute, “Core strengths of the ISSCR include its scientific integrity and excellence, and its outstanding membership comprised of research leaders worldwide.” 

Dr. Mehling is the founder and chief medical officer of BHI Therapeutic Sciences.  He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.

“We are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added. 


Dr. Mehling and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.

Dr. Manvelyan has 15 years of experience in biomedical research and is the author of more than 40 research papers.

She started her research career as a research scientist at Yerevan State University (Armenia) and University Hospital of Jena, Institute of Human Genetic (Germany).

As a Clinical Research Scientist at BHI Therapeutic Sciences, she is conducting scientific research and clinical investigations of adult stem cell therapy for various medical conditions.

The ISSCR promotes the highest scientific and ethical standards and is dedicated to integrity in the rigor and quality of the research community’s scientific work. BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.   Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com

Blue Horizon International CEO Recognized by the International Nurses Association

Doreen Santora, RN, MPH, chief executive officer of Blue Horizon International, will be recognized as a top nurse by the International Nurses Association and will be featured in the publication Worldwide Leaders in Healthcare. 

Ms. Santora is receiving this honor for her outstanding acheivements, commitment to education, and demonstrated leadership in her field. 

“I am grateful to be recognized by the International Nurses Association,” said Ms. Santora. “It is always nice to be recognized, but when you are honored by your colleagues it is even more special,” she added. 

Ms. Santora oversees the operations of Blue Horizon International (BHI) and all of its entities including BHI Therapeutic Sciences, Blue HorizonCharitable Foundation, BHI Rejuve, and Alpha Blu, an innovative skin care line. 

She has nearly 30 years of healthcare management experience, Ms. Santora is a registered nurse with a master’s degree in health administration. She is responsible for the day-to-day operations of the BHI and all its subsidies and places a strong emphasis on quality assurance. Ms. Santora focuses on providing outstanding medical care in a high quality, patient friendly environment. 
Prior to her position here, she served as senior vice president of operations at one of the busiest and most respected healthcare institutions in the United States, Hackensack University Medical Center. 

She was responsible for the growth and development of several nationally and internationally clinical programs that received numerous healthcare awards and distinctions including: outpatient surgery, cardiac surgery, cardiology serves, radiology, sleep medicine, women’s health, executive health, plastic and reconstructive surgery, dermatology, medical spa, pain and palliative care, transfusion-free bloodless medicine, heart failure, and home-based healthcare. Ms. Santora was responsible for more than 1,900 employees and an annual budget of $268 million.

BHI Therapeutic Sciences/ Blue Horizon Stem Cells are the world’s leading provider of adult and children’s stem cell therapies. We have safely and efficiently performed more than 3,000 stem cell research procedures to date. We are the only treatment provider approved and associated with The Wuhan University Department of Medicine, The Biochemistry Institute of Wuhan University. We are fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital near Bratislava, Slovakia.

The International Nurses Association was founded on the idea that professional achievement is deserving of recognition, exposure and reward. INA is the fastest growing network of nurses from around the globe and takes pride in delivering its members the platform and competitive edge needed to survive in this ever-changing and complex environment. They publish the Nurse Advisor Magazine, Nurse2Nurse Newsletter and others that are packed with the latest advice on stress management, sleep improvement, professional organization and salary negotiating. www.inanurse.com also has blogs, articles and links to helpful resources that can improve quality of life at the clinic or at home. These articles are submitted by nurses, physicians and leading lifestyle experts.

IFBB Pro Champion Anton Antipov Hosts Podcast with Dr. Brian Mehling

On August 2nd, 2019 IFBB Pro Champion and professional fitness model Anton Antipov hosts the podcast Gee Talks, and recently had Dr. Brian Mehling on as a guest to have a long, wide-ranging discussion about the potential of stem cell science.  

Antipov has received three stem cell treatments from Dr. Mehling, once in the BHI clinic in Bratislava, Slovakia, and twice in the new Montego Bay, Jamaica clinic, and intends to receive more.

BHI Ambassador and PFL Featherweight Champion Lance Palmer endorses stem cell therapy in BHI Jamaica

Lance Palmer is a featherweight MMA champion who credits stem cell treatments from BHI with a greater feeling of better overall health, more energy, and help with the training recovery process.

Mr. Palmer is a former amateur wrestler and current mixed martial arts fighter. He competes for the Professional Fighters League in the Featherweight division.  A four-time NCAA All-American, Mr. Palmer was a member of the Ohio State wrestling team.

PFL Featherweight Champion Lance Palmer

Mr. Palmer recently won a fight on July 25, 2019 at the  Ocean Casino Resort in Atlantic City, New Jersey via unanimous decision, collecting three regular season points. In the second round Palmer faced Luis Rafael Laurentino at PFL 5. He won the fight via third-round TKO and advanced to the playoffs.

Mr. Palmer has said that his successful treatment at the BHI Jamaica, Montego Bay clinic has helped him become a better fighter. He received his first treatment in 2016 and says it helps with the recovery process, preventing injury, and gave him an overall increase in energy.  Mr. Palmer recommends stem cell treatments in general and Dr. Brian Mehling in particular to all other athletes. He describes his experience in the video above.

BHI Therapeutics Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading institutions, scientists, and physicians across the globe. We only utilize stem cells from either your own body (autologous) or from umbilical cord donors who have proceeded through a multiple step testing process that ensures stem cell patient safety. We do not use embryonic stem cells, nor will we ever.

BHI Therapeutics Jamaica has US board-certified physicians on staff for your safety. Our Scientific Advisory Board and Ethics Committee oversee the disease-specific protocols to ensure the highest standards of patient safety. BHI Therapeutics Jamaica provides therapies for neurological disorders, autoimmune diseases, and orthopedics conditions.

Click here to view our testimonial with Lance Palmer